About Us
Innovative Solutions for Process Analysis
Acuitis Process Analytical Technologies is a leading provider of end-to-end process analytical technology (PAT) applications and engineering solutions. Our experienced PAT scientists and engineers specialize in developing physical devices and systems that are cGMP compliant and certified to operate safely in process environments.
We are dedicated to redefining process analysis with our advanced technology and innovative designs. Our PAT solutions offer exceptional insights and reliability, empowering organizations to make informed decisions and drive efficiency in their processes.
Experienced Specialists
Phil Doherty
CEO at Acuitis Process Analytical Technologies
Phil attained a MChem in Chemistry and Physiology at the University of Sunderland prior to joining Pfizer Global R&D in 1991. He worked there for 12 years in the Technology Development Group, designing & building novel Process Analytical Technology systems for API and Solids Manufacturing applications.
​
Phil was the recipient of the 1997 AAPS Outstanding manuscript of the Year for Quality for pioneering work on the design and implementation of the world’s first Online NIR Blend analysis system. Work on the application of chemical imaging in pharmaceuticals & lab robotics followed. Subsequently Phil worked as the PAT Manager delivering innovative technologies such as Model Predictive Control of High Shear Wet Granulation and Inline measurement systems for Continuous Manufacturing of Pfizer’s biggest selling product.
​
In 2012 Phil founded Process Analytics Ltd, a company specialising in providing total Process Analytical Solutions and Quality-by-Design services to wider the pharmaceutical industry. In 2019 Process Analytics Ltd was acquired by Expo Technologies and became Expo Process Analytics Ltd, where Phil served as Managing Director and Chief Scientific Officer. In 2024 Phil started Acuitis Process Analytics, through which he continues to act as a key scientific consultant and visionary for Expo Process Analytics.
​
In his spare time Phil enjoys photography and travelling.
Steve Hammond
Scientific Consultant
Steve Hammond joined Acuitis PAT in 2024 as a scientific advisor. Steve uses his 39 years of experience as a senior leader at Pfizer, to advise on the technical value proposition for our product offerings, as well as the scientific principles that underpin the individual products.
​
The focus for Steve is to understand the measurement needs of the markets that Acuitis PAT operate in, and to develop an understanding of how process analytical systems and resources can answer those customer needs.
​
Steve’s role as a Senior Director at Pfizer encompassed teams focused on the development and deployment of process analytical technology and material science/ forensic analysis support for Pfizer’s global manufacturing plant network. New product and innovative manufacturing technology introduction were a strategic focus in partnership with Pfizer R&D Groups.
​
A key overall driver for the resources within Steve’s Group was improved supply chain performance.
​
In his spare time Steve is a keen golfer and die-hard Manchester united supporter. Also Steve has an avid interest in history, particularly related to natural history.
Andrew Anderson
Innovator
As a seasoned professional in technology strategy and innovation, Andrew has a proven track record of driving impactful change within product development contexts. One of his key roles has been crafting long-term strategies for the introduction of cutting-edge technologies, aimed at enhancing our product development processes and fostering innovation.
Central to his approach is the creation of comprehensive functional roadmaps that guide the end-to-end application of new technologies. He has led collaborative, cross-functional teams in conducting rigorous proof-of-concept studies to evaluate the feasibility and potential of emerging technologies. Through strategic external collaborations with academic institutions, vendors, and cross-industry partners, he has facilitated the integration of new knowledge and capabilities into our organization, enabling us to stay at the forefront of technological advancements.
A core aspect Andrew's role involves assessing the capabilities of various technologies to drive process understanding and control, ultimately delivering tangible benefits for our business. He has overseen the project management aspects of technology introductions, ensuring seamless integration into our workflows and empowering our research and development teams to achieve continuous process improvements and optimization.
Andrew's contributions have consistently resulted in measurable enhancements to our product development processes, fostering agility, efficiency, and competitiveness in the market. With a keen focus on innovation and a collaborative leadership style, he is committed to driving positive change and delivering value to our organization.
Brad Swarbrick
Managing Director KAX Group
Brad is a world recognised expert in the application of Near and Mid Infrared Spectroscopy, Spectroscopic Imaging and Chemometrics in a number of industrial applications, particularly in the pharmaceutical sector. Brad has worked for and with a number of the largest pharmaceutical, biopharmaceutical and medical device companies to implement innovative control strategies using PAT methodologies. Brad is the current pharmaceutical section editor of the Journal of Near Infrared Spectroscopy and has a Ph.D. in biospectroscopy and advanced chemometrics from the University of Sydney.
